Arnold & Porter Blog

WASHINGTON, D.C., July 13, 2026 — Arnold & Porter is pleased to announce the appointment of Roger Maeda as the firm’s first Chief Artificial Intelligence Officer, reinforcing its commitment to responsible and innovative artificial intelligence and the future of technology-enabled legal services. Roger previously served as Director of Enterprise Applications and Application Development, leading the firm’s enterprise application strategy and software development initiatives.

Pallavi Mehta Wahi, Arnold & Porter Chair of Western U.S. Strategic Growth and head of the firm’s Seattle office, was recently quoted in the Law360 article, “New BigLaw Competition Is Changing The Seattle Market,” discussing the importance of Seattle in the U.S. legal market.

The Federal Deposit Insurance Corporation (FDIC) has proposed its first major update to the rules governing Confidential Supervisory Information (CSI) in roughly three decades.

On June 30, 2026, Judge Mia Roberts Perez of the U.S. District Court for the Eastern District of Pennsylvania denied plaintiff Bryce Martinez’s motion for leave to amend his complaint against 11 major food companies, holding that his proposed First Amended Complaint (FAC) failed to cure the primary defect with his original pleading: the failure to plausibly plead a causal link between any defendant’s ultra-processed foods (UPFs) and his alleged injuries.1 The ruling is the second dismissal in...

Pallavi Mehta Wahi, Arnold & Porter Chair of Western U.S. Strategic Growth and head of the firm’s Seattle office and India practice, was recently quoted in the Puget Sound Business Journal article, “Law firm Arnold & Porter to expand with move to Seattle’s One Union Square,” discussing the firm’s ongoing strategic West Coast growth. Since the firm’s Seattle office opened with just three attorneys in July 2025, the team has steadily grown to more than 40 attorneys and staff.

Daniel Bernstein, Arnold & Porter White Collar Defense & Investigations counsel, was recently quoted in a four-part Anti-Corruption Report series examining the role of compliance representations and warranties in managing legal and regulatory risk. The first article addressed the continuing relevance of compliance reps and warranties.

Advances in genetic medicine, coupled with recent breakthroughs in mental health and weight management, have renewed the scientific community’s attention on the role of biomarkers in the management of disease and development of new therapeutics. Similarly, the success of expedited therapeutic approval programs and a public-private shared interest in speeding the pace of clinical trials has refocused attention on the role of validating new analytes as potential surrogates.

Arnold & Porter recently represented Aurobindo Pharma Limited in obtaining Federal Trade Commission (FTC) clearance for its acquisition of Lannett Company, Inc., a manufacturer of generic pharmaceutical products, in a transaction valued at approximately $250 million. The transaction involved overlapping marketed and pipeline generic pharmaceutical products.

Evan Rothstein, co-chair of Arnold & Porter’s Intellectual Property practice, was quoted in the Law360 article, “Biggest Rulings For Patent Attys In 2026: A Midyear Report,” which examines several of the year's most significant patent decisions from the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit. Evan discussed the Federal Circuit's decision in A.L.M. Holding Co. v.

Letter From the Editors Traditionally, the U.S. Federal Trade Commission (FTC or the Commission) and the Antitrust Division of the U.S. Department of Justice (DOJ or DOJ Antitrust) have used pre-litigation merger settlements to resolve challenged deals. Although such remedies fell out of favor during the Biden administration, FTC and DOJ leadership in both Trump administrations have accepted divestitures to resolve competitive concerns.